That's a hard one isn't it. He may have to sit out of negotiations, but in the end he is in charge of the direction of immuno-oncology at GSK and would be expected to deliver.
It would appear that this science would fit in to the long term goals for all these companies. I agree that this is going to bode very well for Imugene. Time will tell.
Add to My Watchlist
What is My Watchlist?
